多西紫杉醇联合卡铂治疗晚期非小细胞肺癌36例疗效观察

THERAPEUTIC EFFECTS OF DOCETAXEL COMBINED CARBOPLATIN IN TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER: AN ANALYSIS OF 36 CASES

目的:观察多西紫杉醇联合卡铂治疗晚期非小细胞肺癌的临床疗效及不良反应。方法:36例晚期非小细胞肺癌患者给予多西紫杉醇联合卡铂治疗,21天为1个周期,两个周期后评价近期疗效,并观察化疗不良反应。结果:总有效率为38.9%,其中完全缓解(CR)占5.6%(2例),部分缓解(PR)占33.3%(12例),疾病稳定(SD)占36.1%(13例),疾病进展(PD)占25.0%(9例)。毒副反应主要为骨髓抑制,恶心、呕吐等胃肠道反应,无治疗相关性死亡病例。结论:多西紫杉醇联合卡铂治疗晚期非小细胞肺癌有较好的近期疗效,不良反应轻,患者易于耐受,值得临床推广。

Objective：To observe the clinical therapeutic effects and adverse reaction of Docetaxel combined Carboplatin in treatment of advanced non-smal cell lung cancer.Methods：36 advanced non-small lung cancer patients received the same chemotherapy regimens consisting of Docetaxel combined Carboplatin for 21 days as a cycle.The short term effects and adverse reaction were evaluated after 2 cycles.Results：After treatment,the total effective rate was 38.9%： the complete remission rate was 5.6%（2/36）,the partial remission rate was 33.3%（12/36）,the stable disease rate was 36.1%（13/36）,the progression disease rate was 25.0%（9/36）.The main adverse reaction were bone marrow suppression and gastrointestinal reaction,such as nausea and vomiting;No treatment related death cases.Conclusions：Treating advanced non-small cell lung cancer patients with Docetaxel combined Carboplatin can get better therapeatic effects and easily be accepted by patients because of light adverse reaction.